Investor Presentaiton

Jubilant Life Sciences Overview ✓ Radiopharma Pharmaceuticals Specialty Pharmaceuticals Allergy Therapy Products CDMO CMO of Sterile Injectables and Non Sterile Products Active Pharmaceutical Ingredients Generics² Solid Dosage Formulations India Branded Pharmaceuticals (IBP) FY19 Revenue Mix by Segment DDDS 2% Life Sciences Chemicals 23% Nutritional Products 5% Specialty Pharmaceuticals 31% Specialty Intermediates 11% CDMO 16% Generics 12% 100% Rs 9,111 Cr Life Science Ingredients Specialty Intermediates DDDS1 Drug Discovery Services (Jubilant Biosys & Jubilant Chemsys) Nutritional Products Life Sciences Chemicals FY19 Revenue Contribution by Region China and ROW 8% Europe & Japan 14% Proprietary Drug Discovery (Jubilant Therapeutics) FY19 EBITDA Mix by Segment DDDS 1.0% India 27% Life Science Ingredients 24% Pharmaceuticals 75% USA & Canada 51% 100% Rs 9,111 Cr 100% Rs 1,835 Cr USD 1.3 billion integrated global pharmaceuticals and life sciences company Strong position in Specialty Pharmaceuticals – Radiopharma and Allergy Therapy Products 6 USFDA approved manufacturing facilities including 4 in North America and 2 in India; 5 state-of-the-art LSI mfg. facilities in India Expertise in chemistry and manufacturing spanning over four decades of experience ➤ Employs around 8,000 people globally, including over 2,200 in North America and more than 500 dedicated to R&D 1. Drug Discovery & Development Solutions 2. IBP business, earlier presented under segment 'Others' has from Q2'FY20 onwards been reclassified under 'Pharmaceuticals' segment within 'Generics' subsegment JUBILANT LIFESCIENCES

View entire presentation